Skip to content
Search
 
Search
EN  
  • ES
  • DE
  • ZH
   
  • Company
  • Innovation
  • Sustainability
  • Products and services
  • Investors
  • Careers
  • Media
  • Partners
  • Contact
 

Company

Since 1909, Grifols has worked to improve the health and well-being of people around the world.

Read more

  • What we do
    • Biopharma
      • From donors to patients
      • Plasma journey
    • Diagnostic
    • Bio Supplies
    • Healthcare Solutions for Hospitals
  • Mission and values
  • Ethics and compliance
  • Grifols Engineering
    • Engineering
      • Project Management
      • Biotech Processes
      • General Processes
    • Machinery
      • Tailor-made Solutions
      • Pharmaceutical Robotics
      • Standardized Processes
    • Consulting
    • Contact
  • Our history
  • Grifols museum
    • La Casa: where it all began
    • The Plant: people helping people
    • The World: From family business to global company
  • Grifology
    • The Cabinet

Every action we take is motivated by our mission to improve people's lives.

Read more

Our unique and remarkable history combines scientific expertise with a desire to serve patients and society.

Read more

We develop, produce and market innovative medicines, solutions and services in more than 110 countries.

Read more

 

Innovation

Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.  

Read more

  • Plasma Powerhouse
  • Beyond plasma
  • Key therapeutic areas
    • Immunology
    • Hepatology and Intensive Care
    • Pulmonology
    • Hematology
    • Neurology
      • AMBAR®: Research in Alzheimer's Disease
      • AMBAR® Clinical program
    • Infectious Diseases
    • Further Therapeutic Opportunities
  • Extending our innovative reach
    • Team up with Grifols Innovation and New Technologies
    • Scientific Awards and Programs
  • Connecting knowledge - Our R&D network

We apply our growing knowledge of plasma to change healthcare.

Read more

Our treatments are enhancing people’s well-being and quality of life.

Read more

We’re drawing on a broad scientific base to continue innovating.

Read more

 

Sustainability

Grifols' longstanding commitment to people and the planet entails helping society on all fronts.

Read more

  • Commitment to donors and patients
    • Supporting donors
    • Supporting patients
  • Impact on society
  • Our people
  • The environment
  • Ethical leadership
  • Sustainability Reports

2022 Sustainability Report: a detailed overview of our sustainability strategy, actions and progress

Read

Patients drive the work we do every day. We support patients and patient associations.

Learn more

As mindful stewards of the environment we are resolved to fight climate change.

Read more

 
 

Investors

Read more

  • Stock information
    • Stock and share capital
    • Dividends
    • Major holders and treasury stock
    • Agreements between shareholders
    • Analyst coverage
  • Financials
    • Financial results
    • Annual accounts
    • Fixed income and credit ratings
    • Average period of payment to suppliers
  • Press releases
  • Presentations and events
  • Agenda
  • Communications with regulators (CNMV/SEC)
    • CNMV
    • SEC
    • Other relevant information
    • Inside information
    • Relevant events up to Dec. 31st, 2019
  • Corporate Stewardship Reports
  • Corporate governance
    • Board of Directors
      • Committees
      • Regulations
    • General Shareholders’ Meeting
    • Annual corporate governance report
    • Directors' remuneration report
    • Articles of association
    • Corporate policies
  • Mergers
  • Biotest: voluntary takeover offer |
    Freiwilliges übernahmeangebot

Here you can read our Q2 2023 financial results

Read results

Please click here to listen to the webcast of our Q2 2023 financial results

Listen to the webcast

The 2022 Integrated and Sustainability Annual Report is now available

Read more

 

Careers

People are at the heart of our business. We are committed to continued investment in training and development.

Read more

  • Training and development
 

Media

Latest news about the company and contact information for journalists and communication professionals.

Read more

  • Media contacts
  • Newsroom
  • Media Center
 
 

Contact

Read more

  • International Headquarters
  • Adverse reactions – Pharmacovigilance
  • Grifols Ethics Helpline
Search
Show menu
   
Search
com.grifols.labels.close-menu
Company   Innovation   Sustainability   Products and services Investors   Careers   Media   Partners Contact  
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Company What we do   Mission and values Ethics and compliance Grifols Engineering   Our history Grifols museum   Grifology  
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
What we do Biopharma   Diagnostic Bio Supplies Healthcare Solutions for Hospitals
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Biopharma From donors to patients Plasma journey
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Diagnostic
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Bio Supplies
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Healthcare Solutions for Hospitals
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Mission and values
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Ethics and compliance
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Grifols Engineering Engineering   Machinery   Consulting Contact
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Engineering Project Management Biotech Processes General Processes
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Machinery Tailor-made Solutions Pharmaceutical Robotics Standardized Processes
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Consulting
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Contact
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Our history
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Grifols museum La Casa: where it all began The Plant: people helping people The World: From family business to global company
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
La Casa: where it all began
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
The Plant: people helping people
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
The World: From family business to global company
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Grifology The Cabinet
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
The Cabinet
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Innovation Plasma Powerhouse Beyond plasma Key therapeutic areas   Extending our innovative reach   Connecting knowledge - Our R&D network
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Plasma Powerhouse
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Beyond plasma
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Key therapeutic areas Immunology Hepatology and Intensive Care Pulmonology Hematology Neurology   Infectious Diseases Further Therapeutic Opportunities
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Immunology
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Hepatology and Intensive Care
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Pulmonology
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Hematology
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Neurology AMBAR®: Research in Alzheimer's Disease AMBAR® Clinical program
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Infectious Diseases
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Further Therapeutic Opportunities
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Extending our innovative reach Team up with Grifols Innovation and New Technologies Scientific Awards and Programs
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Team up with Grifols Innovation and New Technologies
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Scientific Awards and Programs
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Connecting knowledge - Our R&D network
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Sustainability Commitment to donors and patients   Impact on society   Our people The environment Ethical leadership Sustainability Reports
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Commitment to donors and patients Supporting donors Supporting patients  
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Supporting donors
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Supporting patients
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Impact on society
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Our people
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
The environment
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Ethical leadership
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Sustainability Reports
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Products and services
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Investors Stock information   Financials   Press releases Presentations and events Agenda Communications with regulators (CNMV/SEC)   Corporate Stewardship Reports Corporate governance   Mergers Biotest: voluntary takeover offer |
Freiwilliges übernahmeangebot  
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Stock information Stock and share capital   Dividends Major holders and treasury stock Agreements between shareholders Analyst coverage
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Stock and share capital
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Dividends
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Major holders and treasury stock
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Agreements between shareholders
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Analyst coverage
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Financials Financial results Annual accounts Fixed income and credit ratings Average period of payment to suppliers
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Financial results
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Annual accounts
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Fixed income and credit ratings
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Average period of payment to suppliers
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Press releases
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Presentations and events
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Agenda
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Communications with regulators (CNMV/SEC) CNMV SEC Other relevant information Inside information Relevant events up to Dec. 31st, 2019
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
CNMV
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
SEC
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Other relevant information
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Inside information
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Relevant events up to Dec. 31st, 2019
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Corporate Stewardship Reports
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Corporate governance Board of Directors   General Shareholders’ Meeting   Annual corporate governance report Directors' remuneration report Articles of association Corporate policies
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Board of Directors Committees Regulations
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
General Shareholders’ Meeting
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Annual corporate governance report
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Directors' remuneration report
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Articles of association
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Corporate policies
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Mergers
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Biotest: voluntary takeover offer |
Freiwilliges übernahmeangebot
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Careers Training and development
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Training and development
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Media Media contacts Newsroom Media Center  
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Media contacts
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Newsroom
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Media Center
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Partners
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Contact International Headquarters Adverse reactions – Pharmacovigilance Grifols Ethics Helpline
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
International Headquarters
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Adverse reactions – Pharmacovigilance
English  
  • Spanish
  • German
  • Chinese

Follow

Search
Back
Grifols Ethics Helpline
English  
  • Spanish
  • German
  • Chinese

Follow

BIOTEST:
VOLUNTARY TAKEOVER OFFER
FREIWILLIGES ÜBERNAHMEANGEBOT

Angebotsunterlage (Veröffentlichung 26.10.2021, Deutsch)

Offer Document (publication 26.10.2021, English convenience translation)

Other mandatory publications /
Andere Pflichtpublikationen

Announcement of Clearance in Turkey and Instruction Settlement 12.04.2022

Bekanntmachung der Freigabe für die Türkei inkl. Hinweise zum Vollzug 12.04.2022

Announcement of Clearance in Germany - 08.03.2022

Bekanntmachung der Freigabe fur Spanien - 03.03.2022

Announcement of Clearance in Spain 03.03.2022

Announcement re Modalities of Put Right dates 21-01-2022

Bekanntmachung bzgl. der Modalitäten des Andienungsrechts vom 21.01.2022

Bekanntmachung der Freigabe für Österreich - 22.11.2021(6821588.2)

Announcement of Clearance in Austria – 22.11.2021( 6822807.2)

§ 14 WpÜG Bekanntmachung / Sec 14 WpÜG Announcement

Publication of the decision to make a takeover offer (17.09.2021)

Veröffentlichung der Entscheidung zur Abgabe eines Übernahmeangebotes vom 17.09.2021

Announcements under sec. 23 WpÜG / Bekanntmachungen gemäß § 23 WpÜG

Bekanntmachung gem. § 23 Abs. 2 S. 1 WpÜG vom 02.05.2022

Announcement pursuant sec. 23 para. 2 sentence 1 WpÜG dated 02-05-2022

Bekanntmachung gem. § 23 Abs. 2 S. 1 WpÜG vom 25.04.2022

Announcement pursuant sec. 23 para. 2 sentence 1 WpÜG dated 25-04-2022

Bekanntmachung gem. § 23 Abs. 1 Satz 1 Nr. 3 vom 26.01.2022

Announcement pursuant sec. 23 para. 1 sentence 1 no. 3 WpÜG dated 26-01-2022

Bekanntmachung gemäß § 23 Absatz 1 Satz 1 Nr. 2 und Nr. 4 WpÜG vom 07.01.2022

Announcement pursuant Sec 23 para. 1 sentence 1 no. 2 and no. 4 WpÜG dated 07.01.2022

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 04.01.2022

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 04-01-2022

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 03.01.2022

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 03-01-2022

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 31.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 31-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 30.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 30-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 29.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 29-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 28.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 28-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 21.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 21-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 14.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 14-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 07.12.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 07-12-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 30.11.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 30-11-2021

Bekanntmachung gem. § 23 Abs. 1 S. 1 Nr. 1 WpÜG vom 23.11.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 23-11-2021

Bekanntmachung gem. § 23 Abs. 1 Satz 1 Nr. 1 WpÜG vom 16.11.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 16.11.2021

Bekanntmachung gem. § 23 Abs. 1 Satz 1 Nr. 1 WpÜG vom 09.11.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 09.11.2021

Bekanntmachung gem. § 23 Abs. 1 Satz 1 Nr. 1 WpÜG vom 02.11.2021

Announcement pursuant sec. 23 para. 1 sentence 1 no. 1 WpÜG dated 02.11.2021

Der Inhalt der folgenden Seiten und alle Dokumente im Zusammenhang mit dem Übernahmeangebot sind, trotz der nach deutschem Recht vorgeschriebenen Veröffentlichung im Internet, nicht für die Versendung in Länder bestimmt, in denen dies rechtswidrig wäre, und dürfen dort auch nicht verbreitet, verteilt oder veröffentlicht werden. Allen Investoren und Inhabern von Aktien der Biotest Aktiengesellschaft wird dringend empfohlen, die Angebotsunterlage sowie alle anderen Dokumente vollständig zu lesen, da sie wichtige Informationen und Hinweise enthalten.
The content of the following pages and documents related to the takeover offer are not intended and cannot be sent to or disseminated, distributed or published in countries in which this would be illegal, despite the publication in the internet required by German law. All investors and holders of shares in Biotest Aktiengesellschaft are strongly advised to read the offer document in its entirety as well as all other documents because they contain important information and notices.

OK
Cancel / Abbruch

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

Follow

© 2023 Grifols, S.A. All rights reserved worldwide.

ABOUT US

Company

Sustainability

Innovation

Products & services

Investors

Careers

Media

TOP WEBSITES

Grifols Plasma

The Grifols Academy of Plasmapheresis

Grifols Scientific Awards

Grifols Engineering

Grifols Egypt for Plasma Derivatives

Victor Grifols i Lucas Foundation

Probitas Foundation

J.A. Grifols Foundation

HELP

Privacy notices

Cookies policy

Cookie Settings

Terms of use

Contact

Glossary

© 2023 Grifols, S.A. All rights reserved worldwide.